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Personalized medicineCD22ΔE12has emerged as a driver lesion in the pathogenesis of pediatric B-lineage acute lymphoblastic leukemia
(ALL) and a new molecular target for RNA therapeutics. Here we report a 43-gene CD22ΔE12 signature tran-
scriptome that shows a striking representation in primary human leukemia cells from patients with relapsed
BPL. Our data uniquely indicate that CD22ΔE12 is a candidate driver lesion responsible for the activation of
MAPK and PI3-K pathways in aggressive forms of B-lineage ALL. We also show that the forced expression of a
CD22 RNA trans-splicing molecule (RTM) markedly reduces the capacity of the leukemic stem cell fraction of
CD22ΔE12+ B-lineage ALL cells to engraft and cause overt leukemia in NOD/SCID mice. We have successfully
complexed our rationally designed lead CD22-RTM with PVBLG-8 to prepare a non-viral nanoscale formulation
of CD22ΔE12-RTM with potent anti-cancer activity against CD22ΔE12+ B-lineage leukemia and lymphoma
cells. CD22-RTM nanoparticles effectively delivered the CD22-RTM cargo into B-lineage ALL cells and exhibited
signiﬁcant anti-leukemic activity in vitro.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Contemporary treatment strategies offer N80% long-term survival in
pediatric B-lineage ALL (O'Leary et al., 2008). However, the prognosis of
relapsed B-lineage ALL is very poor (Gaynon et al., 2006; Pui et al.,
2012). New treatment strategies capable of improving the treatment out-
comes of relapsed B-lineage ALL patients are urgently needed. Leukemic
clones in aggressive forms of pediatric B-lineage ALL are characterized
by CD22ΔE12, a genetic defect involving CD22, an inhibitory co-
receptor of human BCP (Uckun et al., 2010, 2014a, 2015a; Ma et al.,
2011). The incidence of CD22ΔE12 is also high in adult aggressive
B-lineage leukemias and lymphomas (Uckun et al., 2015a). We haveith Research Tower Suite 300-
LA Mailstop 160, Los Angeles,
. This is an open access article underpreviously demonstrated that therapy-refractory clones in B-lineage ALL
patients are CD22ΔE12+ (Ma et al., 2011). Notably, CD22ΔE12-
transgenic (Tg)mice spontaneously develop B-lineage ALLwhich recapit-
ulates the gene expression proﬁle of CD22ΔE12+ human B-lineage ALL,
establishing a causal relationship between CD22ΔE12 and B-lineage ALL
and indicating that CD22ΔE12 is an oncogenic “driver lesion” sufﬁcient
for leukemogenesis (Uckunet al., 2014a). Functional RNA interference ex-
periments using CD22ΔE12-speciﬁc siRNA and its nanoscale formulations
have conﬁrmed the causal link between CD22ΔE12 and the stemness fea-
tures as well as aggressiveness and drug resistance of B-lineage ALL cells
(Uckun et al., 2014a,2014b, 2015b). Our most recent preliminary studies
have established that the “undruggable” CD22ΔE12 genetic defect can
be repaired using RNA trans-splicing molecules (RTM) (Uckun et al.,
2015a). The aim of the current study was to further assess the anti-
leukemic activity of CD22-RTM on clonogenic B-lineage ALL cells and to
characterize a unique multi-functional nanoparticle (NP) of CD22-RTM
as a novel anti-ALL nanomedicine candidate.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Bioinformatics and Statistical Analysis of Gene Expression Proﬁles
The Exon 12 Index valueswere calculated by subtracting themedian
centered expression values of the Exon 10–11 plus Exon 13–14 probesfrom the median centered expression values of the Exon 12 probes, as
previously reported (Uckun et al., 2014a, 2015a). In order to determine
the representation of the leading-edge genes of the CD22ΔE12 tran-
scriptome in the transcriptome of primary leukemia cells from relapsed
BPL patients, the RMA-normalized gene expression values for leukemia
cells obtained from 49 BPL patients in relapse (GSE28460) were log2
651F.M. Uckun et al. / EBioMedicine 2 (2015) 649–659transformed and mean-centered to the average value for the 447
diagnosis samples (GSE11877, GSE13351, GSE28460, and GSE7440)
for cluster visualization. To determine the differential expression of
each leading edge gene of the CD22ΔE12 transcriptome in relapsed
BPL cells, linear contrasts designed from a mixed ANOVA model using
RMA normalized expression values were performed, as reported
(Uckun et al., 2014a).
2.2. Gene Expression Proﬁling of Murine BPL Cells and Gene Set Enrichment
Analysis (GSEA)
Mouse leukemia cells were isolated frommarkedly enlarged spleens
of CD22ΔE12-Tg, BCR-ABL-Tg or Eμ-MYC Tg mice, Splenocytes from
wildtype healthy C57BL/6 mice served as controls. Gene expression
values for splenocytes fromWThealthy C57/BL/6mice (N=4), leukemia
cells from CD22ΔE12-Tg mice (N = 2), leukemia cells from BCR-ABL Tg
mice (N = 2), and leukemia cells from Eμ-MYC Tg mice (N = 2) were
estimated from RMA normalization of signal values following hybridiza-
tion to the Affymetrix Mouse Gene 1.0 ST Array (1,102,500 probes,
35,512 genes) (GSE58874 and GSE58872), as previously reported
(Uckun et al., 2014a,2014b). PM signal values for probesetswere extract-
ed utilizing raw CEL ﬁles matchedwith probe identiﬁers obtained from a
CDF ﬁle (MoGene-1_0-st-v1, r3.cdf obtained from http://www.aroma-
project.org/vignettes/GeneSTArrayAnalysis) implemented by Aroma
Affymetrix statistical packages run in the R-studio environment (Version
0.97.551, R-studio Inc., running with R 3.01). The PM signals were quan-
tiﬁed using Robust Multiarray Analysis (RMA), as previously reported
(Uckun et al., 2014a,2014b). T-values greater than 5 (2035 genes) or
less than−5 (1973 genes) of log2 gene expression differences between
BPL cells from CD22ΔE12-Tg mice (N= 2) vs. other cells (N= 8; pooled
data on wildtype normal splenocytes and BPL cells from BCR-ABL Tg or
Eμ-MYC Tg mice) were visualized using a one-way hierarchical cluster
ﬁgure to organize similar expression proﬁles of genes across the sam-
ples. Transcript cluster annotations for the mouse array were obtained
from the NetAffx website (http://www.affymetrix.com/Auth/analysis/
downloads/na33/wtgene-32_2/MoGene-1_0-st-v1.na33.2.mm9.
transcript.csv.zip). In order to determine a CD22ΔE12-speciﬁc gene
expression signature, the expression levels for differentially expressed
genes were compared for BPL cells from CD22ΔE12-Tg mice versus
splenocytes from WT mice, BPL cells from CD22ΔE12-Tg versus Eμ-
MYC Tg mice and BPL cells from CD22ΔE12-Tg versus BCR-ABL Tg mice
using Student's T-tests (unequal variance correction). T- and P-values
were obtained for further processing in the GSEA (accession nos. GSE
58872 and 58874).
Weused 3 archived gene expression proﬁling datasets (i.e., GSE13159,
GSE1187, and GSE13351) and log2-transformed RMA normalized gene
expression values (Assay Platform: Human Genome U133 Plus 2.0
Array) on primary leukemia cells from newly diagnosed pediatric ALL
patients to perform pairwise correlations of the Exon 12 Index for
each sample and signaling pathway-linked probesets for 3 cytogeneti-
cally deﬁned high-risk BPL subsets (N = 279) – Ph+/BCR-ABL+ (N =
123), t (1;19)/E2A-PBX1+ (N = 61), multilineage leukemia gene MLL
rearranged (MLL-R+) (N = 95) – and 74 normal control samples.
Correlation coefﬁcients (r)were determined between CD22Exon 12 ex-
pression and each of the probesets for GSEA. Rank-ordered correlation
coefﬁcients were processed for enrichment of the signaling pathway
(viz.: MAPK pathway, PI3-K pathway, WNT pathway) -linked gene setsFig. 1. CD22ΔE12 signature transcriptome in human and mouse BPL cells. Depicted are GSE plo
ordered correlation coefﬁcients (y-axis expression of each probeset plotted against CD22 Exon 12
sets obtained from the Reactome Database (c2.cp.reactome.v4.0.symbols deposited in database o
Institute). Probesets for (i) “MAPK targets/nuclear events mediated by MAP kinases” pathway (p
(iv) WNT pathway (panel D) negatively correlated with Exon 12 transcript levels in human BPL s
ulated upon loss of CD22 Exon 12 (enrichment observed towards the negative correlation coefﬁc
derived from CD22ΔE12-Tgmice (enrichment observed towards negative T-values depicting gen
scores for expression change inmouse and human transcriptomeswere combined using Fisher'sm
mouse cells (combined P-value).obtained from the Reactome Database (c2.cp.reactome.v4.0.symbols
deposited in database on broadinstitute.org servers) using a supervised
approach implemented inGSEA2.08 (Broad Institute). Signiﬁcance of as-
sociation was assessed using weighted Kolmogorov–Smirnov statistics.
The GSEA evaluated the signiﬁcance of the over-representation of
probesets correlated or anti-correlated with CD22 Exon 12 Index values
by calculating the enrichment score (ES) values representing the differ-
ence between the observed rankings from the expected null. The null
distribution assumed a random rank distribution utilizing an empirical
permutation test procedure that randomly assigned probeset names
to the rank ordered differences in expression (“GSEA Preranked”
algorithm). Leading edge genes were identiﬁed up to and including
the peak of the ES proﬁle. Nominal P-values were computed by compar-
ing the tails of the ES scores for observed and permutation-generated
null distributions following 1000 permutations. The T-values of the
gene expression differences between CD22ΔE12-Tg BPL cells and other
cells were processed for enrichment using gene sets obtained from the
Reactome Database (c2.cp.reactome.v4.0.symbols deposited in database
on broadinstitute.org servers) using a supervised approach implement-
ed in GSEA2.08 (Broad Institute), as described (Uckun et al., 2014b).
T-values obtained from comparisons of CD22ΔE12-Tg BPL cells versus
WT splenocytes, CD22ΔE12-Tg BPL cells versus Eμ-MYC Tg BPL cells
and CD22ΔE12-Tg BPL cells versus BCR-ABL Tg BPL cells were utilized
to identify consistently and uniquely dysregulated signaling pathways
in CD22ΔE12-Tg BPL cells. In order to more directly compare gene set
enrichments in BPL cells from CD22ΔE12-Tg mice with loss of CD22
Exon 12 in high risk human BPL, T-values of the differences between
CD22ΔE12-Tg BPL cells versusWT splenocytes, Eμ-MYC Tg BPL cells or
BCR-ABL Tg BPL cells were processed for GSEA and compared to the
GSEA results obtained from the correlation with Exon 12 Index values
in 3 cytogenetically deﬁned high-risk BPL subsets focusing on MAPK,
PI3-K andWNT pathway signaling pathways. Signiﬁcance of association
was assessed using weighted Kolmogorov–Smirnov statistics. To com-
pare the differences in gene expression levels across gene sets, normal-
ized enrichment scores (NES) were calculated. A two-way hierarchical
cluster analysis of the NES values was performed to visualize the associ-
ations between gene sets in comparisons of CD22ΔE12-Tg BPL cells
versusWT splenocytes, CD22ΔE12-Tg BPL cells versus Eμ-MYC Tg BPL
cells and CD22ΔE12-Tg BPL cells versus BCR-ABL Tg BPL cells. A more
focused analysis on MAPK, WNT and PI3-K/AKT pathway genes as clas-
siﬁed in the Reactome Database was performed because of their associ-
ation with relapsed human BPL. In this comparison, nominal P-values
for GSEA enrichment scores for expression changes in mouse and
human transcriptomeswere combined using the Fisher's method to de-
termine the signiﬁcance of the representation of signaling pathway
genes in both human and mouse BPL cells (combined P-value) (Uckun
et al., 2014b).
2.3. Phosphoproteome Analysis Using Antibody Microarrays
The phosphoproteome analyses were performed as previously de-
scribed in detail (Uckun et al., 2014a). Data were normalized utilizing
the median intensity values for the 1318 antibodies on each array
(normalized data = average signal intensity of replicate spots/median
signal). The normalized data were log10 transformed and mean
centered to the WT samples (N = 4, 2 technical replicates for each of
2 samples) (GSE58873 and GSE 58874).ts comparing the human vs.mouse CD22ΔE12 signature transcriptomes in BPL cells. Rank-
Index on the x-axis) were processed for enrichment of the signaling pathway-linked gene
n broadinstitute.org servers) using a supervised approach implemented in GSEA2.08 (Broad
anel A), (ii) MAPK pathway (panel B), (iii) PI3-K/mTOR activation pathway (panel C), and
amples from high-risk ALL patients indicating that the transcripts were differentially upreg-
ient values). The mouse homologs of these genes were also upregulated in murine BPL cells
es downregulated inWT/BCR-ABL/Eμ-MYC Tgmice). Nominal P-values for GSEA enrichment
ethod to determine the signiﬁcance of the representation of the pathway in both human and
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Deidentiﬁed xenograft clones from2 relapsed B-lineage ALL patients
were used in this study. The secondary use of these clones did not meet
the deﬁnition of human subject research per 45 CFR 46.102 (d and
f) and the IRB (CCI) at the Children's Hospital Los Angeles (CHLA) ap-
proved our research. In addition, the B-lineage ALL cell lines ALL-1
and RAJI (B-ALL/Burkitt's leukemia) were used in some of the
experiments.2.5. Construction of the CD22 RNA-trans-splicing Molecule (RTM)
Transfection of ALL Xenograft Cells from Relapsed B-lineage ALL Patients
With CD22-RTM
The CD22-RTM was designed to replace the mutated segment
of CD22 intron 12 and downstream portion of the CD22ΔE12
gene with mutation-free wildtype CD22 Exons 10–14 (Uckun et al.,
2015a). We have constructed a plasmid that expresses an RTM
with a rationally designed anti-sense binding domain (also known
as the trans-splicing region or TSR) targeting a 60-nt complementary
non-coding region close to the 5′ splice site of CD22 Intron 9 that
confers speciﬁcity by tethering the RTM to its target pre-mRNA
(Uckun et al., 2015a). B-lineage ALL xenograft cells were transfected
with the CD22-RTM plasmid using standard procedures, which were
previously described in detail (Uckun et al., 2015a). As in earlier work,
untransfected cells, cells transfected with an empty control plasmid
(EPL) as well as cells transfected with a dystrophin-RTM plasmid
were used as controls (Uckun et al., 2015a). Transfection and trans-
splicing in leukemia cells were conﬁrmed by using RT-PCR as reported
(Uckun et al., 2015a).2.6. NOD/SCID (NS) Mouse Xenograft Model of Human B-lineage ALL
The anti-leukemic activity of CD22-RTM against leukemic stem cells
was studied in a previously published NS mouse xenograft model of
human B-lineage ALL (Uckun et al., 2013, 2015b,2015c). The research
was approved by the IACUC of CHLA. Our standard animal care proce-
dures were previously reported (Uckun et al., 2015d, 2015e). In 2 inde-
pendent experiments, we examined the effects of CD22-RTM on the
leukemia-initiating cells of the xenograft clones. Controls included
untransfected cells. Immediately after transfection, cells were injected
into NS mice. NS mice (6–8 weeks old, female, same age in all cohorts
in each independent experiment) were inoculated intravenously (i.v)
with CD22-RTM transfected B-lineage ALL xenograft cells (2 × 106
leukemia cells in 0.2 mL PBS). Miceweremonitored daily and electively
euthanized by CO2 asphyxia when anymouse developedmorbidity.We
compared the spleen size and nucleated spleen cell counts of mice ac-
cording to the leukemia cells they were inoculated with. Spleens of
micewere removed andmeasured, and cell suspensions were prepared
for determination of mononuclear cell counts. For multiple group com-
parisons, signiﬁcant treatment effects were determined using linear
contrasts for all pairwise comparisons deﬁned by an ANOVA model
with one ﬁxed factor for treatment (6 comparisons for a model
consisting of 4 treatment groups: untransfected cells (N = 5), cells
transfected with CD22-RTM (N = 17), EPL (N = 17), or Dystrophin-
RTM (N = 5)). Two separate models were constructed for spleen size
and log10 transformed nucleated spleen cell counts using previously
published standard procedures (Uckun et al., 2013, 2015c). Compari-
sons of 2 treatment groups (pooled controls (N = 27) versus CD22-
RTM treated (N= 17)) were performed using a two-tailed T-test. Con-
tingency analysis compared the proportion of mice with splenomegaly
(spleen size N 3 cm) and a high nucleated spleen cell count (N150
million nucleated cells/spleen) in pooled control versus CD22-RTM
treated groups.2.7. Preparation and Characterization of CD22-RTM Nanoparticles
PVBLG-8, a helical, cationic polypeptide, was prepared, as previously
reported (Yin et al., 2013a,2013b; Zheng et al., 2014; Uckun et al.,
2014a). CD22-RTM was complexed with PVBLG-8 at a 1:10 weight
ratio to form the NPs. Control NP were prepared with a luciferase
encoding control plasmid (pLuc), Dystrophin-RTM plasmid, and empty
plasmid (EPL). Size measurement by the dynamic light scattering
(DLS) method and Zeta potential analyses were performed using
a Malvern Zetasizer, as previously reported (Uckun et al., 2013; Yin
et al., 2013b). Transmission electron microscopy (TEM) was performed
using published procedures (Uckun et al., 2013; Yin et al., 2013b).
CD22-RTM condensation by PVBLG-8 at a PVBLG-8/CD22-RTM weight
ratio of 10:1 was evaluated by a gel retardation assay, as previously
reported (Zheng et al., 2014, 2015). For the CD22-RTM + serum or
PVBLG-8/CD22-RTM + serum conditions, CD22-RTM or PVBLG-8/
CD22-RTM were incubated with fetal bovine serum for 2 h at 37 °C,
respectively. For PVBLG-8/CD22-RTM + serum/heparin, after incuba-
tion with serum, a 10-fold excess of heparin was added to remove the
CD22-RTM from the NP. In order to perform a ﬂow cytometric analysis
of the cellular delivery of ﬂuorescent-labeled CD22-RTM by PVBLG-8/
CD22-RTM NP, CD22-RTM DNA was labeled with YOYO1 and YOYO1-
CD22 RTMwas complexedwith PVBLG-8 to form theNP using previous-
ly published methods (Zheng et al., 2014, 2015). Unformulated YOYO1-
CD22 RTM vs. PVBLG-8/YOYO1-CD22 RTM NP were incubated with
CD22ΔE12+ RAJI or ALL-1 (BCR-ABL+ B-lineage ALL) cells (0.5 μg
DNA/sample) for 4 h. After 2 washes with heparin-supplemented PBS
to remove the NP attached to the membrane of leukemia cells, cells
were ﬁxed with paraformaldehyde (4%, 100 μL) and analyzed for
cell-associated ﬂuorescence due to internalized YOYO1-CD22 RTM
using ﬂow cytometry. To evaluate the ability of CD22-RTM NP to
cause transfection and trans-splicing in CD22ΔE12+ B-lineage leuke-
mia cells, the difﬁcult to transfect RAJI cells in 1 mL culture medium
were incubated for 4 h at 37 °C with PVBLG-8 (50 μg)/CD22-RTM
(5 μg), PVBLG-8 (50 μg)/Dystrophin-RTM (5 μg), or PVBLG-8 (50 μg)/
empty plasmid (EPL) (5 μg). Cells were washed twice and then cultured
in RPMI + 10% FBS for 48 h at 37 °C/5% CO2. Total RNA was extracted
from the 48 h samples and subjected to RT-PCR analysis as described
above and outlined in the ﬁgure legends. The anti-leukemic activity of
theCD22-RTMagainst RAJI cellswas evaluatedusingMTT assays to assess
cell viability.
The CD22-RTM NP delivers expression plasmids that encode
CD22-RTM. Upon delivery to the nucleus, the plasmid's CMV pro-
moter drives expression of the RTM as RNA. If normal or mutant
CD22 pre-mRNA is present in the cell, the RTM binding domain can
base-pair with its complementary region in CD22 intron 9. The 3′
splice site carried by the RTM can recruit splicing factors (such as
U2 and U2AF) to bind to the RTM. These factors can interact and
begin the splicing process in trans — with other splicing factors
(such as U1) that are bound to the 5′ splice site of the endogenous
CD22 intron 9, thereby replacing the entire sequence of endogenous
CD22, beginning with intron 9 and including Exon 14 as well as the 3′
UTR, with the exogenous sequence of CD22 EXONs 10 through 14
provided by the RTM. Each trans-spliced molecule of CD22ΔE12 pre-
mRNA is converted or reprogrammed to encode normal CD22 mRNA.
Therefore, the reduction in the amount of CD22ΔE12 mRNA is directly
proportionate to the number of mutant pre-mRNA molecules trans-
spliced. The total amount of trans-spliced CD22 mRNAs includes both
the number of mutant and normal CD22 pre-mRNAs that are trans-
spliced. Our RTM will trans-splice into both mutant and normal CD22
pre-mRNA, with the result that the mutant is corrected to encode a nor-
mal CD22 sequence, while the normal is trans-spliced into normal,
although both forms will be tagged with the 3′ UTR sequence of the
RTM. The net effect on the leukemic phenotype should correlate with
the amount that the mutant leukemogenic CD22ΔE12mRNA expression
is reduced.
Fig. 2. Signature transcriptome of CD22ΔE12 transgenic (Tg) BPL cells. Gene expres-
sion values for splenocytes from WT healthy C57BL/6 mice (N = 4), leukemia cells
from CD22ΔE12 Tg mice (N = 2), leukemia cells from BCR-ABL Tg mice (N = 2),
and leukemia cells from MYC Tg mice (N = 2) were estimated from RMA normaliza-
tion of signal values following hybridization to the Affymetrix Mouse Gene 1.0 ST
Array (1102500 probes, 35512 genes). Expression values for each probeset were
standardized across the 10 samples and differences in expression were visualized
using a one-way hierarchical cluster ﬁgure to organize similar expression proﬁles of
genes across the samples. Heat map depicts up- and downregulated transcripts rang-
ing from red to blue respectively and clustered according to average distance metric
(panel A). We determined a unique CD22ΔE12 signature transcriptome from signiﬁ-
cantly affected expression values comparing CD22ΔE12 Tg BPL cells with BPL cells
from Eμ-MYC Tg or BCR-ABL Tg mice as well as WT splenocytes. T-tests documented
that 49 probesets representing 43 signaling pathway genes in MAPK, PI3-K and WNT
signaling networks were signiﬁcantly upregulated in CD22ΔE12-Tg mice (P b 0.05).
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3.1. CD22ΔE12-Driven Signature Transcriptome is a Characteristic Feature
of Aggressive Leukemic Clones in Newly Diagnosed High Risk ALL as well as
Relapsed B-lineage ALL
Relapse clones are characterized by constitutive activation of
mitogen-activated protein kinase (MAPK) pathways (Hogan et al.,
2011). Likewise, constitutive activation of the phosphatidylinositol 3-
kinase (PI3-K), Akt and the mammalian target of rapamycin (mTOR)
(PI3-K/Akt/mTOR) network is a characteristic feature of aggressive
BPL cells (Badura et al., 2013; Neri et al., 2013). However, the driver
lesion that causes these transcriptome changes in aggressive BPL cells
has remained elusive. The GSEA of primary leukemia cells from 279
cytogenetically deﬁned high-risk BPL patients and normal hematopoi-
etic cells in 74 control samples showed that the expression of genes re-
lated to MAPK, PI3-K/mTOR, and WNT pathways was differentially
upregulated upon the loss of the CD22 Exon12 (Fig. 1). Gene expression
proﬁling and GSEA revealed differential upregulation of the mouse ho-
mologs of these genes in BPL cells from CD22ΔE12-Tgmice – but not in
BPL cells from Eμ-MYC Tg or BCR-ABL Tg mice – closely mimicking the
transcriptome of primary leukemia cells from high-risk BPL patients
(Figs. 1, 2A). We identiﬁed a CD22ΔE12 signature transcriptome
based on the signiﬁcantly affected expression values of the leading
edge genes from the GSEA by comparing CD22ΔE12-Tg BPL cells with
BPL cells from Eμ-MYC Tg or BCR-ABL Tg mice as well as wildtype
splenocytes (Fig. 2A): T-tests documented that 49 probesets representing
43 signaling pathway genes inMAPK, PI3-K andWNT signaling networks
were signiﬁcantly upregulated in CD22ΔE12-Tgmice (P b 0.05) (Fig. 2B).
A comparative proteomic proﬁling with phosphoprotein antibody arrays
demonstrated that 37 phosphoproteins in MAPK and PI3-K signaling
networks were uniquely overexpressed in CD22ΔE12-Tg BPL cells
(Fig. 3; GSE58873 and GSE58874). These changes collectively demon-
strate that the regulation of multiple signaling networks is corrupted in
CD22ΔE12-Tg BPL cells. We next examined the representation of the
unique CD22ΔE12 signature transcriptome in primary cancer cells from
patients with relapsed BPL by comparing the gene expression proﬁles
of primary leukemia cells from 447 newly diagnosed BPL patients vs. pri-
mary leukemia cells from 49 relapsed BPL patients using a mixed model
ANOVA. Notably, there was a signiﬁcant overall increase in expression
of 110 probesets in aggressive BPL cells from relapsed BPL patients
(F1,494 = 68.7, P b 0.0001) (Fig. 4). Our ﬁndings indicate that the
CD22ΔE12 genetic defect is the likely genetic cause for the activation of
MAPK, PI3-K/mTOR and WNT pathways in primary leukemia cells from
relapsed BPL patients. CD22ΔE12 may therefore have clinical utility as a
molecular biomarker of aggressive relapse clones in high-risk BPL
patients and a potential molecular target for more effective treatment
of poor prognosis B-lineage ALL.
3.2. Effects of CD22-RTM Mediated Trans-splicing on In Vivo Clonogenic
CD22ΔE12+ B-lineage Leukemia Cells
We recently demonstrated that transfection of BPL cells with CD22-
RTM causes selective depletion of the CD22ΔE12-mRNA and clonogenic
death in vitro (Uckun et al., 2015a). These promising results prompted
us to examine the anti-leukemic potency of CD22-RTM mediated
trans-splicing against the leukemia-initiating cells (LIC) (i.e., putative
“leukemic stem cell fraction”) of chemotherapy-resistant aggressive
xenograft clones from 2 patients with relapsed B-lineage ALL. Xenograft
clones were transfected with CD22-RTM, Dystrophin-RTM (negative
control), or empty plasmid (EPL, another negative control). RT-PCR as-
says performed48h after transfection conﬁrmed successful transfection
and trans-splicing in xenograft cells (Fig. 5A–C). Immediately after
transfection, an aliquot of xenograft cells was injected into NS mice.
All of the 27 control mice injected with untransfected (N = 5), EPL-
transfected (N = 17), or Dystrophin-RTM transfected xenograft cells
Fig. 3. Signature phosphoproteome of CD22ΔE12 transgenicmouse BPL cells. The phosphoprotein proﬁles of CD22ΔE12-Tg BPL cells were compared side-by-sidewith those of Eμ-MYC Tg
BPL cells, BCR-ABL Tg BPL cells aswell asWT splenocytes from healthy C57BL/6mice by using the Phospho Explorer Antibody Array platform (Full Moon BioSystems, Inc., Sunnyvale, CA),
as described inMaterials andMethods. Datawere normalized utilizing themedian intensity values for the 1318 antibodies on each array. The normalized datawere log10 transformed and
mean centered to theWTC57BL/6 splenocyte samples (N=4, 2 technical replicates for each of 2 samples). (A)Heatmapdepicts up- and downregulated protein expression levels ranging
from red to green respectively. Expression values weremean centered toWT samples and clustered according to average distancemetric. (B) Student's T-tests (unequal variance correc-
tion,Microsoft Excel) comparedmean-centered, log10 transformedprotein expression levels in BPL cells fromCD22ΔE12 Tgmice vs. splenocytes fromWTmice andBPL cells fromBCR-ABL
Tg or MYC Tg mice. P-values and effect sizes in SD units are shown for differentially expressed proteins.
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Necropsy revealed massive (N3 cm) splenomegaly at the time of
death in 26 of these 27 mice (Fig. 5D–F). In contrast, only 3 of 17 NS
mice developed overt leukemia within the same time frame after rein-
jection with CD22-RTM transfected xenograft cells (2-Tailed Fisher's
exact, P b 0.0001). The spleens of the control mice injected with
untransfected xenograft cells were very large (3.3 ± 0.1 cm) with avery high leukemia burden (622 ± 110 × 106 cells/spleen) (Fig. 5D).
Likewise, the spleens were large and contained large numbers of leuke-
mia cells (3.3 ± 0.1 cm/562 ± 40 × 106 cells and 3.2 ± 0.1 cm/335 ±
41 × 106 cells, respectively) in control mice injected with xenograft
cells that were transfected with an irrelevant RTM (viz.: Dystrophin-
RTM) or EPL (Fig. 5E). For the entire group of 27 control mice, the
mean ± SEM values for the spleen size and leukemia burden were
Fig. 4. Expression of CD22ΔE12 transcriptome in relapsed BPL cells. The 43-genemouse CD22ΔE12-Tg transcriptomewas represented by 110 probesets on the humanU133 Plus 2.0 Array.
The RMA-normalized gene expression values for leukemia cells from 49 BPL patients in relapse (GSE28460) were log2 transformed and mean-centered to the average value for the 447
diagnosis samples (GSE11877, GSE13351, GSE28460, and GSE7440). Mixed model ANOVA showed signiﬁcant overall increase in expression of 110 probesets in relapsed cases (F1,494 =
68.7, P b 0.0001). (A) The gene expression values were clustered according to average distance metric. Heat map depicts up- and downregulated transcripts ranging from red to green
respectively for expression valuesmean centered to diagnosis samples. (B) To determine the differential expression of each leading edge gene of the CD22ΔE12 transcriptome in relapsed
BPL cells, linear contrasts were performed for the RMA normalized values (P b 0.05 deemed signiﬁcant). 33 probesets were upregulated and 5 downregulated with P b 0.0001 and fold
change greater than 2.
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to the control mice, the spleens of the 17 test mice injected with
CD22-RTM transfected xenograft cells had a signiﬁcantly smaller size(2.3 ± 0.1 cm, P-value b 0.0001) and leukemia burden (110 ±
21 × 106 cells/spleen, P-value b 0.0001), respectively (Fig. 5D &E).
While 26 of the 27 control mice had very high (N150× 106 cells/spleen)
Fig. 5. CD22-RTM abrogates the ability of leukemia-initiating ALL xenograft cells derived from B-lineage ALL patients to cause leukemia in NS mice. B-lineage ALL xenograft cells (2 × 106
cells/sample) were transfected with 5 μg CD22-RTM plasmid DNA using the Amaxa Nucleofector Kit and then inoculated into NS mice (N= 17) intravenously via tail vein injections in a
200 μL total volume. Controls included NS mice inoculated with untransfected xenograft cells (N = 5), xenograft cells transfected with 5 μg empty plasmid (EPL) (N= 17) or xenograft
cells transfected with 5 μg Dystrophin-RTM (N= 5) prior to inoculation. Mice were monitored for signs of leukemia and all mice in a given experiment were sacriﬁced when any mouse
developed morbidity. (A–C) RT-PCR analyses of xenograft clone #1 transfected with CD22-RTM vs. control plasmids conﬁrming transfection and successful completion of trans-splicing.
Total RNA for the PCR was extracted 2 days after transfection. CON: untransfected cells. (A) An agarose gel is depicted showing the RT-PCR ampliﬁcation of a 415-bp RTM-speciﬁc RNA-
segment ampliﬁed by RT-PCR using a CD22 Exon 11 primer as forward primer (EX11-F) and the RTM IRES primer RTM-4494-5263 as a reverse primer (IRES-R). The detection of the
amplicon provides evidence for the successful transfection of ALL xenograft cells with the CD22-RTM. (B) Successful completion of selective CD22 RTM-induced trans-splicing in B-lineage
ALL xenograft cells was evidenced by speciﬁcally amplifying a 763-bp trans-splicedmRNA segment using an Exon 9 forward primer (EX9-F) and a reverse primer in the IRES sequence of
the RTM (IRES-R), as previously reported (Uckun et al., 2015a). (C) An agarose gel of the RT-PCR products obtained with the EX4-F/EX4-R primer set that was used as a positive control of
RNA integrity is shown. (D and E) The cumulative results for the average spleen size and nucleated spleen cell count are shown for each treatment group, respectively. (F) Spleen images
from representative mice are shown. The spleen images were obtained using an iPhone 4S equipped with an 8-megapixel iSight camera.
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den, only 4 of the 17mice inoculatedwith CD22-RTM transfected xeno-
graft cells had such high nucleated spleen cell counts (2-Tailed Fisher's
exact, P b 0.0001). Thus, transfectionwith CD22-RTMmarkedly reduced
the in vivo clonogenicity of the leukemic stem cell fraction of
CD22ΔE12+ B-lineage ALL cells.
3.3. Development and Characterization of a Polypeptide-based CD22-RTM
Nanoparticle Formulation as an Anti-leukemic Precision Nanomedicine
We have successfully complexed CD22-RTM with PVBLG-8 at a
PVBLG-8/RTM weight ratio of 10:1 to prepare a nanoparticle (NP)formulation capable of delivering CD22-RTM to B-lineage ALL cells
(Fig. 6). The generated PVBLG-8/CD22-RTM nanoparticles had a
diameter of 105 nm, as determined by dynamic light scattering
(DLS) and conﬁrmed by transmission electron microscopy (TEM)
(Fig. 6A), and a positive surface charge with a Zeta potential of
39.4 mV in solution (Fig. 6B). The capacity of the cationic PVBLG-8
to condense CD22-RTM plasmid DNA was ﬁrst evaluated using the
gel retardation assay, as previously reported (Zheng et al., 2015).
As shown in Fig. 6C, DNA migration in the 1% agarose gel was
completely restricted to the loading well, indicating complete
condensation of the CD22-RTM by the positively charged PVBLG-8.
Furthermore, while the naked RTM DNA rapidly degraded in the
Fig. 6. PVBLG-8-based nanoparticle (NP) formulation (NPF) of CD22-RTM. (A) DLS analysis of PVBLG-8/RTM (weight ratio 10:1) nanoparticles, showing a particle size around 105-nm in
diameter and with a narrow polydispersity index of 0.192. Insert: TEM image of PVBLG-8/RTM NP. (B) Zeta-potential result of PVBLG-8/RTM NP, showing that the NP were positively
charged. (C) CD22-RTM condensation by PVBLG-8 at a PVBLG-8/CD22-RTM weight ratio of 10:1, as evaluated by a gel retardation assay, as previously reported (Zheng et al., 2014). For
the CD22-RTM + serum or PVBLG-8/CD22-RTM + serum conditions, CD22-RTM or PVBLG-8/CD22-RTM was incubated with serum for 2 h at 37 °C, respectively. For PVBLG-8/CD22-
RTM + serum/heparin, after incubation with serum, a 10-fold excess heparin was added to remove the CD22-RTM from the NP. (D) Flow cytometric analysis of the cellular delivery of
ﬂuorescent-labeled CD22-RTM by PVBLG-8/CD22-RTMNP. Unformulated YOYO1-CD22 RTM vs. PVBLG-8/YOYO1-CD22 RTMNPwere incubatedwith CD22ΔE12+ RAJI (Burkitt's lympho-
ma/leukemia) or ALL-1 (BCR-ABL+ B-lineage ALL) cells (0.5 μg DNA/sample) for 4 h. After 2 washes with heparin-containing PBS to remove membrane-bound NP, cells were ﬁxed with
paraformaldehyde (4%, 100 μL) and analyzed for cell-associated ﬂuorescence caused by internalized YOYO1-CD22 RTM using ﬂow cytometry. Markedly improved CD22-RTM delivery to
RAJI and ALL-1 cells was conﬁrmed for the NP formulation by the higher cell-associated ﬂuorescence intensity in samples incubated with PVBLG-8/YOYO1-CD22 RTM vs. unformulated
YOYO1-CD22 RTM. RTM: in this ﬁgure, abbreviation for CD22-RTM. (E) RAJI cells in 1 mL culture medium were incubated for 4 h at 37 °C with PVBLG-8 (50 μg)/CD22-RTM (5 μg),
PVBLG-8 (50 μg)/Dystrophin-RTM (5 μg), or PVBLG-8 (50 μg)/empty plasmid (EPL) (5 μg). Cells were washed twice and then cultured in RPMI + 10% FBS for 48 h at 37 °C/5% CO2.
Total RNA was extracted from the 48 h samples and subjected to RT-PCR analysis. Depicted is an agarose gel that shows the RT-PCR evidence for successful transfection and trans-
splicing, as described in the legend of Fig. 5. Also depicted is an agarose gel showing the RT-PCR ampliﬁcation of β-actin mRNA (as a control for RNA integrity) with a forward primer
5′-GGACTTCGAGCAAGAGATGG-3′, and a reverse primer 5′-AGCACTGTGTTGGCGTACAG-3′. This primer set ampliﬁes a 234-bp region at the junction between Exon 4 and Exon 5 of the
human beta actin gene. (F) Anti-leukemic activity of PVBLG-8/CD22-RTM nanoparticles. Depicted are the MTT viability assay data showing the anti-leukemic effects of PVBLG-8
(50 μg)/CD22-RTM (5 μg) NP vs. control NP PVBLG-8 (50 μg)/pLuc (5 μg) on RAJI and ALL-1 cells.
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RTM + serum vs. PVBLG-8/RTM + serum). The NP formulation effec-
tively delivered CD22-RTM into leukemia cells (Fig. 6D), effectivelytriggered trans-splicing (Fig. 6E), and exhibited anti-leukemic activity,
as documented by loss of leukemic cell viability within 48 h after a 4 h
incubation period with the NP (Fig. 6F).
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We are reporting that the CD22ΔE12 genetic defect is the likely
genetic cause for the activation of MAPK, PI3-K/m-TOR and WNT
pathways in primary leukemia cells from relapsed BPL patients.
These pathways have been associated with chemotherapy resistance
and aggressiveness of BPL cells. By comparing CD22ΔE12-Tg BPL cells
with BPL cells from Eμ-MYC Tg or BCR-ABL Tg mice as well as wildtype
splenocytes, we have identiﬁed a unique 43-gene CD22ΔE12 signature
transcriptome that showed a striking representation in primary human
leukemia cells from patients with relapsed BPL. CD22ΔE12 may there-
fore have clinical utility as a molecular biomarker of aggressive relapse
clones in high-risk BPL patients and a potential molecular target for
more effective treatment of poor prognosis B-lineage ALL.
RNA trans-splicing has been used to repair several mutant genes
linked to human disease (Tahara et al., 2004; Mitchell and McGarrity,
2005; He et al., 2015).Wehave also documented CD22ΔE12 as an onco-
genic driver lesion and an undruggable molecular target in aggressive
B-lineage leukemia cells (Uckun et al., 2014a,2014b, 2015a,2015b).
Our CD22-RTM was designed to replace the mutated segment of CD22
intron 12 and the downstream portion of the CD22ΔE12 gene with
mutation-free wildtype CD22 Exons 10–14 (Uckun et al., 2015a). Here
we show that the forced expression of the CD22-RTMmarkedly reduces
the in vivo clonogenicity of the leukemic stem cell fraction of CD22ΔE12+
B-lineage ALL cells.
We have recently developed a highly efﬁcient nucleic acid delivery
platform based on a class of rationally designed cell-penetrating cat-
ionic helical polypeptides (Lu et al., 2011; Gabrielson et al., 2012; Yin
et al., 2013a,2013b; Uckun et al., 2014a; Zheng et al., 2014). These
polypeptide-based novel nanomaterials exhibit unprecedented ther-
modynamic and physicochemical stability and unique biological prop-
erties with exceptional endosomal escape and nucleic acid delivery
efﬁciency. The high molecular weight, cationic, α-helical polypeptide
PVBLG-8 was identiﬁed as the top-performing peptide for nucleic acid
delivery in vivo with favorable safety, biocompatibility, PK, and bio-
distribution proﬁles (Yin et al., 2013a,2013b; Zheng et al., 2014). We
have successfully complexed our rationally designed lead CD22-RTM
with PVBLG-8 to prepare a “non-viral” nanoscale formulation of
CD22-RTM with potent anti-cancer activity against CD22ΔE12 B-
lineage leukemia and lymphoma cells. CD22-RTM nanoparticles effec-
tively delivered the CD22-RTM cargo into B-lineage ALL cells and exhib-
ited signiﬁcant anti-leukemic activity in vitro.
The focus of our future preclinical proof of concept studies in animal
models of B-lineage ALL studies will be a stepwise evaluation of the
safety, biocompatibility, pharmacodynamics features, and efﬁcacy of
this polypeptide-based nanoscale formulation of CD22-RTM. We aim
to establish spliceosome-mediated RNA trans-splicing using polypep-
tide-based multifunctional nanoparticles of the CD22-RTM as a thera-
peutic innovation to treat chemotherapy-resistant B-lineage ALL.
Therapeutic nanoformulations containing CD22-RTM may facilitate
the development of effective treatments for patients with relapsed
B-lineage ALL. The CD22-RTM technology is applicable to all B-lineage
ALL patients both high risk and standard risk. That is because
CD22ΔE12 is a characteristic feature of leukemic clones that escape
chemotherapy and cause relapse in both high risk and low risk sub-
groups of patients. The technology therefore has the potential (i) for
prevention of relapses by selectively killing the clones that are most
likely to escape chemotherapy and cause relapse aswell as (ii) for treat-
ment of relapses in ALL.
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